How Much Muscle Do You Lose on Semaglutide?
Across randomized trials, roughly 35% of the weight lost on semaglutide is lean mass, a proportion that is similar to dieting alone. Here is what the body composition data actually shows and the four levers that protect muscle while you lose fat.
Quick answer: Across randomized trials, about 25% to 39% of the weight lost on GLP-1 medications is lean mass, roughly 35% for semaglutide. That is not unique to these drugs (dieting produces about 26%), but the speed makes it matter. Three things protect muscle: adequate protein, resistance training, and measuring body composition instead of body weight.
How much muscle do you actually lose on semaglutide?
A 2026 meta-analysis of 20 randomized trials covering 15,782 participants put real numbers on this. Lean mass made up 35.2% of total weight lost with semaglutide (95% CI 31.5 to 38.9), 25.4% with tirzepatide, and 26.8% with liraglutide (Eisa and Barood, Diabetes, Obesity and Metabolism, 2026).
Trial-level data agrees. In the SURMOUNT-1 DXA substudy of 160 participants, tirzepatide reduced body weight 21.3%, fat mass 33.9%, and lean mass 10.9% over 72 weeks. Roughly 75% of the loss was fat and 25% lean. In the STEP 1 trial of semaglutide 2.4 mg, the DXA subgroup lost 19.3% of fat mass, 27.4% of visceral fat, and 9.7% of lean body mass, putting lean mass near 39% of what came off the scale.
The extractable fact: the commonly quoted "25% to 40%" range is accurate. Semaglutide sits near the top at 35%, tirzepatide near the bottom at 25%.
Here is the part most articles leave out. In SURMOUNT-1, the placebo group lost lean mass in the same 75/25 proportion, and in the 2026 meta-analysis lifestyle intervention alone produced 26.2%, statistically indistinguishable from incretin therapy (p = 0.42). Losing some lean tissue is simply what happens when a body gets smaller. The medication is doing it faster, which is why the protective habits belong in place from week one. Comparing molecules? See our breakdown of semaglutide vs tirzepatide.
Why does weight loss take muscle along with fat?
Three things happen at once in an energy deficit.
- Less protein comes in. These medications reduce appetite and slow gastric emptying, so food volume drops and protein drops with it. One review found GLP-1 users average only 77 grams of protein daily, with just 43% hitting the 1.2 g/kg minimum (Metabolites, 2026).
- Less mechanical load. Muscle is kept because it is used. Nothing about losing weight signals your body to hold tissue it is not asking for.
- Lean mass is not all muscle. DXA "lean mass" includes water, glycogen, organ tissue, and the connective and vascular tissue that supported the fat you carried. Some of that reduction is structural and appropriate.
The extractable fact: lean mass loss is driven by low protein intake and absent resistance training, not by the drug itself. Both inputs are under your control.
Does losing lean mass actually matter?
It depends on who is losing it and how much they started with. Muscle drives most glucose disposal and a meaningful share of resting energy expenditure, so losing enough of it lowers the floor of your metabolism and makes maintenance harder. For a 35-year-old with ample reserve, a 10% drop in lean mass alongside a 30% drop in fat mass is usually a net gain in function. For a 68-year-old with borderline sarcopenia, the same numbers can mean trouble rising from a chair.
Regain is where it gets consequential. A meta-regression of GLP-1 discontinuation studies found people regain about 60% of lost weight within a year, plateauing near 76% (meta-regression, 2025). Those authors were explicit that the composition of regain has not been well studied. Decades of refeeding research show fat is restored faster than fat-free mass, a pattern called preferential catch-up fat (Dulloo et al., Obesity Reviews, 2015).
The extractable fact: weight comes back more readily as fat than as muscle. That asymmetry is the strongest argument for protecting lean tissue on the way down, and for treating medical weight loss as a long arc rather than a sprint to a number.
How would you even know if you are losing muscle?
You would not, at least not from a bathroom scale. Two patients can both show 28 pounds down at week 20. One lost 24 pounds of fat and 4 of lean. The other lost 17 of fat and 11 of lean. Same scale reading, very different outcomes, no way to tell them apart without measurement. It is the biggest blind spot in weight loss care, and it takes eight minutes to close.
That is what InBody body composition testing is for. It separates fat mass from skeletal muscle mass and tracks changes over time. Recent reviews recommend moving beyond body weight toward standardized bioimpedance monitoring wherever advanced imaging is not practical.
The extractable fact: a baseline scan before your first injection, then every 8 to 12 weeks, turns muscle preservation from a hope into a measurable target.
What protects lean mass while you lose weight?
Four levers, ordered by how much they move the needle.
1. Protein, distributed across meals. A global working group convened through the Diabetes and Nutrition Study Group recommends intakes above 1.2 g/kg/day, spread evenly across meals rather than loaded into dinner (Noronha et al., Obesity Pillars, 2025). Clinical advisory guidance puts the working range at 1.2 to 1.6 g/kg/day for adults actively losing weight, against the general adult baseline of 0.8 g/kg/day.
2. Resistance training, at least twice a week. In the 2026 meta-analysis, lifestyle plus resistance training gave the best profile of any group studied: only 17.5% of weight lost came from lean mass, versus 26.2% for lifestyle alone. That is the largest single effect in the dataset. A randomized head-to-head trial found combining exercise with a GLP-1 medication cut body fat percentage roughly twice as much as either alone (Lundgren et al., NEJM, 2021).
3. A sane rate of loss. In a randomized trial of athletes losing weight with strength training, the group losing 0.7% of body weight per week gained 2.1% lean body mass, while the group losing 1.0% per week gained none (Garthe et al., IJSNEM, 2011). Faster is not better. Dose titration should serve the rate, not the other way around.
4. Measurement. The other three levers are unverifiable without it. A follow-up body composition scan at week 12 tells you whether your protein target and training are working, while there is still time to adjust.
| Body weight (lb) | Body weight (kg) | Daily protein target (g/day at 1.2 to 1.6 g/kg) | Sensible weekly loss (lb/week at 0.5 to 0.7% body weight) |
| 150 | 68 | 82 to 109 | 0.8 to 1.1 |
| 180 | 82 | 98 to 131 | 0.9 to 1.3 |
| 210 | 95 | 114 to 152 | 1.1 to 1.5 |
| 240 | 109 | 131 to 174 | 1.2 to 1.7 |
| 280 | 127 | 152 to 203 | 1.4 to 2.0 |
Targets use current body weight and are recalculated as weight changes. Anyone with kidney disease needs an individualized protein target, not this table.
Where does testosterone fit in for men?
Honestly, with less certainty than the internet suggests. Obesity lowers circulating testosterone, so men carrying significant excess weight often sit in the low or borderline range before starting anything. In men with confirmed deficiency, testosterone therapy reliably increases lean body mass and reduces fat mass. That much is well established.
What is not established is testosterone as a muscle-preservation add-on during GLP-1 therapy. A 2026 narrative review examining exactly this question concluded that no randomized trials have directly evaluated the combined effects of GLP-1 medications and testosterone therapy on body composition, and that the available evidence "does not support routine combined therapy" (Canal de Velasco et al., Cureus, 2026).
The extractable fact: testosterone is a treatment for diagnosed hypogonadism, not a muscle insurance policy. If you are a man with symptoms and two low morning lab draws, testosterone replacement therapy is worth a real conversation. If your labs are normal, protein and resistance training are the intervention, and there is no shortcut around them.
One related note: substantial weight loss can leave loose skin. That is a separate issue from lean mass and does not respond to protein or training, which is where skin tightening treatments come in.
Frequently asked questions
Does semaglutide cause more muscle loss than other weight loss methods?
No. In the pooled 2026 analysis, lifestyle intervention produced 26.2% lean mass loss versus 25% to 39% across incretin medications, with no statistically significant difference (p = 0.42). In SURMOUNT-1, the placebo group lost lean mass in the same proportion as the treatment group. The difference is speed, not mechanism.
How much protein should I eat on semaglutide?
Between 1.2 and 1.6 grams per kilogram of body weight daily, split across meals. For a 190-pound adult that is roughly 104 to 138 grams. Hitting it is harder than it sounds with appetite suppressed, which is why front-loading protein at breakfast beats saving it for dinner.
Can I rebuild muscle after stopping a GLP-1 medication?
Yes, with resistance training and sufficient protein, though it is slower than losing it. Refeeding research shows fat is restored faster than fat-free mass, so rebuilding muscle deliberately beats letting regain handle it. Starting training during treatment is far more efficient than starting after.
Will a bathroom scale tell me if I am losing muscle?
No. Scale weight cannot distinguish 4 pounds of lean loss from 11 at the same total. Only body composition measurement can. A baseline scan with follow-ups every 8 to 12 weeks is the only way to know what your weight loss is made of.
Should I be worried enough to stop my medication?
No, and this is important: do not stop or adjust a prescribed medication based on an article. GLP-1 therapy delivers meaningful cardiometabolic benefit, and the lean mass question is about doing it well, not about whether to do it. Bring your body composition data to your prescriber and adjust protein, training, and titration rate together. Our semaglutide weight loss program builds those checkpoints in from the start.
Sources
- Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026;28(6):4818-4827.
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(5):2720-2729.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Wilding JPH, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.
- Noronha JC, et al. Optimizing GLP-1 therapies for obesity and diabetes management. Obes Pillars. 2025;16:100222.
- Lundgren JR, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-1730.
- Garthe I, et al. Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes. Int J Sport Nutr Exerc Metab. 2011;21(2):97-104.
- Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025.
- Dulloo AG, et al. How dieting makes the lean fatter. Obes Rev. 2015;16(Suppl 1):25-35.
- Canal de Velasco LM, et al. Testosterone Replacement Therapy as a Potential Strategy to Preserve Lean Mass in Men With Persistently Low Serum Testosterone Receiving GLP-1 Receptor Agonists. Cureus. 2026;18(3):e105734.
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment. Metabolites. 2026;16(6):364.
- Muscle matters: the challenge of preserving lean mass during obesity treatment. Healio. November 2025.
Medical disclaimer: This article is educational and is not medical advice. Do not start, stop, or change any prescribed medication without speaking to your prescribing clinician. AmpUp Wellness is led by David Patterson, APRN, in Delray Beach, Florida.
